Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14573MR)

This product GTTS-WQ14573MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14573MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12759MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ9103MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ15071MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ2940MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ6647MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ8906MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ12419MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ11281MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW